Genetic polymorphisms in UGT enzymes can lead to significant inter-individual variability in drug metabolism and toxicity. For instance, variations in the UGT1A1 gene can affect the metabolism of irinotecan, a chemotherapeutic agent, resulting in severe toxicity in some patients. Identifying such polymorphisms through pharmacogenetic testing can guide personalized medicine approaches, optimizing drug dosing and minimizing adverse effects.
